Dendritic Cell Marker Panel for Precise Pro-Inflammatory Identification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods struggle to clearly delineate mononuclear phagocyte subsets, particularly dendritic cells, due to overlapping phenotypes and functional ambiguities, which hinders understanding of their roles in health and disease.
Innovation Solution
A method involving the determination of CD5, CD14, and CD163 expression in dendritic cells to identify and characterize pro-inflammatory dendritic cells, including CD163+CD14+ cells as highly pro-inflammatory, and use of related kits for detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional phenotypic markers are used to identify dendritic cell subsets, then classification can be performed, but the overlapping phenotypes result in imprecise identification and characterization
Solution Approach 1:
The patent segments the identification process by dividing the marker panel into functional groups: core identity markers (CD11c, HLA-DR), subset-defining markers (CD1c, CD141, CD143), and pro-inflammatory markers (CD5, CD14, CD163). This segmentation allows systematic identification of dendritic cell subsets through a structured approach that reduces confusion from phenotype overlap.
Solution Approach 2:
The patent changes the identification parameters by incorporating pro-inflammatory markers (CD5, CD14, CD163) alongside traditional dendritic cell markers. This parameter expansion enables differentiation of pro-inflammatory dendritic cell subsets (pDC1, pDC2, cDC1, cDC2) based on their inflammatory marker expression profiles, resolving the precision issue caused by overlapping traditional phenotypes.
2Measurement precision
If multiple markers are used to characterize dendritic cells, then subset identification improves, but the method complexity and difficulty of detection increase
Solution Approach 1:
The patent organizes the multi-marker detection into segmented functional categories: identity markers for confirming dendritic cell lineage, subset markers for distinguishing major lineages (pDC vs cDC), and pro-inflammatory markers for identifying activated states. This segmentation simplifies the detection process by providing a logical framework for interpreting complex multi-parameter flow cytometry data.
Solution Approach 2:
The patent employs a universal marker panel that serves multiple functions simultaneously: CD11c and HLA-DR confirm dendritic cell identity, while CD1c, CD141, and CD143 distinguish subsets, and CD5, CD14, and CD163 identify pro-inflammatory states. This multi-functional marker set enables comprehensive characterization in a single detection workflow, reducing overall complexity despite the number of markers used.
3Measurement precision
If pro-inflammatory markers CD5, CD14, and CD163 are determined in dendritic cells, then precise identification of pro-inflammatory subsets is achieved, but the method requires additional reagents and analysis steps
Solution Approach 1:
The patent merges the identification of dendritic cell subsets with the assessment of their inflammatory state by combining traditional subset markers (CD1c, CD141, CD143) with pro-inflammatory markers (CD5, CD14, CD163) in a single integrated method. This merging allows simultaneous determination of both lineage identity and functional state, achieving precise identification of pro-inflammatory subsets without requiring separate assays.
Solution Approach 2:
The patent creates a universal characterization method that uses a combined marker panel serving dual purposes: defining dendritic cell subset identity and assessing pro-inflammatory activation. The same reagent set and analysis workflow identify both the lineage (pDC or cDC) and the inflammatory state, making the kit composition efficient despite the comprehensive nature of the characterization.
Data Source
AI summary
There is provided a method of identifying pro-inflammatory dendritic cells, the method comprising: determining an expression of CD5, CD14 and/or CD163 in cells, wherein CD5−, CD14+ and/or GD163+ cells are identified as pro-inflammatory dendritic cells. Also disclosed is a method of characterising inflammation and/or inflammatory disease in a subject, the method comprising: determining a proportion of CD5−, CD14+ and/or GD163+ dendritic cells in the subject's sample, wherein the proportion positively correlates with the level of inflammation and/or the severity of inflammatory disease in the subject.